Drugs / 20-valent pneumococcal conjugate vaccine
20-valent pneumococcal conjugate vaccine
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 37 trials | ||||||
| Phase 3 | NCT05875727 | Aug → Oct 2023 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT05512819 | Sep 2022 → Sep 2025 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT05408429 | Jun 2022 → Jun 2023 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT04530838 | Sep 2020 → Apr 2022 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT04546425 | Sep 2020 → Apr 2022 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT04379713 | May 2020 → Aug 2022 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT04382326 | May 2020 → Sep 2022 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07135427 | Sep 2025 → Mar 2027 expected | alpha 1-antitrypsin deficiency, chronic obstructive pulmonary disease, immunodeficiency disease | University of Alabama at Birmingham | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07086677 Comparator | Jul 2025 → Oct 2027 expected | pneumococcal infection | Pfizer | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06524414 Comparator | Jul 2024 → May 2027 expected | pneumococcal infection | Pfizer | Active not recruiting | No outcome recorded |
Press releases naming this drug 18 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-10-23 | Pfizer | Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older pfizer.com ↗ |
| 2023-04-27 | Pfizer | U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children pfizer.com ↗ |
| 2023-01-06 | Pfizer | U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children pfizer.com ↗ |
| 2022-09-19 | Pfizer | Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union pfizer.com ↗ |
| 2022-08-12 | Pfizer | Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants pfizer.com ↗ |
| 2022-02-15 | Pfizer | European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults pfizer.com ↗ |
| 2021-12-17 | Pfizer | CHMP Issues Positive Opinion for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults pfizer.com ↗ |
| 2021-05-24 | Pfizer | Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults pfizer.com ↗ |
| 2021-02-26 | Pfizer | European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older pfizer.com ↗ |
| 2020-12-08 | Pfizer | U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older pfizer.com ↗ |
| 2020-10-21 | Pfizer | Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020 pfizer.com ↗ |
| 2020-05-14 | Pfizer | Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age pfizer.com ↗ |
| 2020-03-18 | Pfizer | Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older pfizer.com ↗ |
| 2019-09-09 | Pfizer | Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants pfizer.com ↗ |
| 2019-04-13 | Pfizer | Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older pfizer.com ↗ |
| 2019-02-28 | Pfizer | Pfizer Announces Serotypes Included in 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older pfizer.com ↗ |
| 2018-12-14 | Pfizer | Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older pfizer.com ↗ |
| 2018-09-20 | Pfizer | Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older pfizer.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 20-valent pneumococcal conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05408429 ↗ |
| Known as | 20-valent PCV | “This phase 3, single-arm study evaluated the safety and immunogenicity of 20-valent PCV (PCV20) in adults ≥18 y of age in India.” PMID 41504209 ↗ Jan 2026 |
| Known as | 20vPnC | “The purpose of this study is to understand the safety and effects of a study vaccine (20vPnC) in toddlers who had 2 prior doses of Prevnar 13.” NCT05408429 ↗3“The purpose of this study is to understand the safety and effects of a study vaccine (20vPnC) in infants and toddlers.” NCT05512819 ↗ “Participants will receive a single dose of study vaccine (20vPnC) into the arm at visit 1” NCT05875727 ↗ “20-valent pneumococcal conjugate vaccine (20vPnC)” NCT06524414 ↗ |
| Known as | PCV20 | “This phase 3, randomized, partially double-blind study investigated the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine (PCV20) in healthy...” PMID 40081152 ↗ Mar 20255“This phase 3, double-blind study randomized healthy Japanese infants to receive 4 doses (3 infant doses, 1 toddler dose) of PCV20 by subcutaneous (SC) or intramuscular (IM)...” PMID 38242195 ↗ Jan 2024 “The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to extend pneumococcal disease protection beyond 13-valent PCV (PCV13).” PMID 38535409 ↗ Mar 2024 “This phase 3, single-arm study evaluated the safety and immunogenicity of 20-valent PCV (PCV20) in adults ≥18 y of age in India.” PMID 41504209 ↗ Jan 2026 “Here, we describe the safety and immunogenicity of routinely recommended pediatric vaccines given with 20-valent-PCV (PCV20).” PMID 41187484 ↗ Nov 2025 “the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer)” NCT07135427 ↗ |
| Modality | Vaccine | “20-valent pneumococcal conjugate vaccine” NCT04379713 ↗ |
| Route | Intramuscular | “20-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)” NCT04530838 ↗ |
| Route | Subcutaneous | “20-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)” NCT04530838 ↗ |